TCM
CORT icon

TD Capital Management’s Corcept Therapeutics CORT Stock Holding History

TD Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-136
Closed -$4.73K – 871
2025
Q4 		$4.73K Buy
136
+7
+5% +$550 ﹤0.01% 528
2025
Q3 		$10.7K Hold
129
– – ﹤0.01% 411
2025
Q2 		$9.47K Buy
+129
New +$9.35K ﹤0.01% 423

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

TD Capital Management's CORT Position: Q1 2026 in Review

TD Capital Management sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 136 shares — an estimated $4.73K sold.

TD Capital Management first reported a position in CORT in Q2 2025 and held it in 3 quarters. The position peaked at $10.7K in Q3 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • TD Capital Management reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • TD Capital Management sold 136 Corcept Therapeutics shares in Q1 2026, an estimated $4.73K.
  • TD Capital Management first reported a position in Corcept Therapeutics in Q2 2025 and held it in 3 quarters.
  • TD Capital Management's Corcept Therapeutics position peaked at $10.7K in Q3 2025.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on TD Capital Management's 13F filing for Q1 2026, filed 11 May 2026.